We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Redx Pharma Plc | LSE:REDX | London | Ordinary Share | GB00BSNB6S51 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 10.25 | 10.00 | 10.50 | 10.25 | 10.25 | 10.25 | 39,464 | 08:00:14 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.2M | -33.16M | -0.0852 | -1.20 | 39.87M |
From Apr 2019 to Apr 2024
TIDMREDX
RNS Number : 8141I
Redx Pharma plc
22 June 2017
22 June 2017
REDX PHARMA PLC (in administration)
("Redx" or "the Company")
Update on Suspension of Trading
Redx, the drug discovery and development company, is today providing an update on developments since the announcement of the suspension of its shares from trading on the AIM market of the London Stock Exchange and the appointment of Jason Baker and Miles Needham of FRP Advisory LLP as joint administrators (the "Joint Administrators") on 24 May 2017.
The Joint Administrators are working with the Company's advisers on proposals to rescue Redx and return the Company to the control of its directors, with the intention of lifting the suspension and restoring trading in the ordinary shares.
Discussions regarding these proposals are at a relatively early stage and there can be no guarantee that these will be concluded successfully in the short term.
A further announcement will be made in due course, as and when appropriate.
For further information, please contact:
Hot Features
Premium
Redx Pharma Plc (in administration)
Contact for the Joint Administrators: T: + 44 203
James Rossiter (Morgan Rossiter) 195 3240
Cantor Fitzgerald Europe (Nomad & T: +44 20
Broker) 7894 7000
Phil Davies/ Michael Reynolds
WG Partners LLP (Joint Broker) T: +44 20
3705 9330
Claes Spång/ Chris Lee/ David
Wilson
About Redx Pharma Plc (in administration)
Company website: redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDDBGDLCGDBGRB
(END) Dow Jones Newswires
June 22, 2017 02:00 ET (06:00 GMT)
1 Year Redx Pharma Chart |
1 Month Redx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
